英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

scrambled    音标拼音: [skr'æmbəld]
a. 不规则的;杂乱的
n. 加密编码;扰频

不规则的;杂乱的加密编码;扰频

scrambled
杂混的>

scrambled
搅拌

scrambled
adj 1: thrown together in a disorderly fashion; "a scrambled
plan of action"

Scramble \Scram"ble\, v. i. [imp. & p. p. {Scrambled}; p. pr. &
vb. n. {Scrambling}.] [Freq. of Prov. E. scramb to rake
together with the hands, or of scramp to snatch at. cf.
{Scrabble}.]
1. To clamber with hands and knees; to scrabble; as, to
scramble up a cliff; to scramble over the rocks.
[1913 Webster]

2. To struggle eagerly with others for something thrown upon
the ground; to go down upon all fours to seize something;
to catch rudely at what is desired.
[1913 Webster]

Of other care they little reckoning make,
Than how to scramble at the shearer's feast.
--Milton.
[1913 Webster]

67 Moby Thesaurus words for "scrambled":
aimless, amalgamated, ambiguous, ambivalent, amphibious,
beyond one, blended, combined, complex, complicated, composite,
compound, compounded, conglomerate, crabbed, cramp, dappled,
designless, difficult, eclectic, empty, equivocal, fifty-fifty,
garbled, half-and-half, hard, hard to understand, heterogeneous,
importless, inane, indiscriminate, insignificant, intricate,
ironic, jumbled, knotty, many-sided, meaningless, medley, mingled,
miscellaneous, mixed, motley, multifaceted, multinational,
multiracial, nonconnotative, nondenotative, null, obfuscated,
obscure, obscured, overtechnical, patchy, perplexed, phatic,
pluralistic, promiscuous, purportless, purposeless, senseless,
syncretic, thrown together, tough, unmeaning, unsignificant,
varied

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • FDA approves cemiplimab-rwlc for adjuvant treatment of . . .
    On October 8, 2025, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals Inc ) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma
  • Libtayo (cemiplimab-rwlc) FDA Approval History - Drugs. com
    Libtayo (cemiplimab-rwlc) is a programmed death receptor-1 (PD-1) blocking antibody for the treatment of cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma (BCC), and non-small cell lung cancer (NSCLC)
  • FDA approves Regenerons Libtayo for high-risk CSCC
    The US Food and Drug Administration (FDA) has granted approval to Regeneron Pharmaceuticals’ fully human monoclonal antibody Libtayo (cemiplimab-rwlc) as an adjuvant therapy for adults with cutaneous squamous cell carcinoma (CSCC) The approval is intended for patients who face an increased risk of the disease returning after surgery and radiation
  • FDA Approves Cemiplimab as Adjuvant Immunotherapy for High . . .
    Last week, Regeneron announced the U S Food and Drug Administration (FDA) approval of cemiplimab-rwlc (Libtayo) as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (CSCC), particularly in those with a high risk of recurrence after surgery and radiation 1 The PD-1 inhibitor was evaluated under priority review
  • FDA Approves Libtayo for Immunotherapy for Adjuvant Treatment . . .
    FDA approved of Regeneron Pharmaceutical’s Libtayo (cemiplimab-rwlc)as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (CSCC) who are at an increased risk of recurrence following surgery and radiation 1 Libtayo was reviewed by FDA under Priority Review, a method reserved for medicines representing a potential improvement in efficacy or safety in treatments of
  • Behind the FDA Approval: Adjuvant Cemiplimab Shifts Treatment . . .
    Vishal A Patel, MD, discusses the FDA approval of cemiplimab in cutaneous squamous cell carcinoma On October 8, 2025, the US FDA approved the immunotherapy cemiplimab-rwlc (Libtayo) for adjuvant treatment of adult patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence
  • LIBTAYO® (cemiplimab-rwlc) in Advanced NSCLC, BCC, CSCC . . .
    Learn about LIBTAYO® (cemiplimab-rwlc) in the treatment of advanced NSCLC, BCC, CSCC, as an adjuvant treatment for high-risk CSCC Review Important Safety Info Full Prescribing Information including Med Guide
  • FDA Approvals Roundup: Libtayo | RAPS
    FDA Approvals Roundup: Libtayo A weekly update on new drug approvals and indications from the US Food and Drug Administration (FDA) New indications Libtayo gets extended indication for NSCLC with high PD-L1 expression Regeneron’s Libtayo (cemiplimab-rwlc injection) has been approved as a first-line therapy for advanced non‒small cell lung cancer (NSCLC) in patients whose tumors have high
  • Cemiplimab-rwlc as first and only treatment for advanced . . .
    Introduction: In September of 2018, the United States Federal Drug Administration (FDA) approved cemiplimab-rwlc (Libtayo) for advanced cutaneous squamous cell carcinoma (CSCC)
  • FDA Approves Libtayo for Adjuvant Treatment of High-Risk CSCC
    The FDA has approved Libtayo for the adjuvant treatment of adult patients with CSCC at high risk of recurrence after surgery and radiation





中文字典-英文字典  2005-2009